Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech Aborts Raptiva Amidst Reports Of Fatal Brain Infection

This article was originally published in The Pink Sheet Daily

Executive Summary

Risk management program couldn't save psoriasis drug. Decision is final, firm says.
Advertisement

Related Content

Biogen Seeks Tysabri Magic TOUCH Again: REMS Allows Rapid PML Response
Roche Wins Genentech After Months-Long Battle
Hamburg, Sharfstein Appointments To FDA Shift Focus To Future Plans Of Career Officials
Can A REMS Save Raptiva? Tysabri-Style Program Would Mean Restrictions
Can A REMS Save Raptiva?
Raptiva PML Case Brings Another REMS
FDA Amendments Act: More Regulation = More Comfort and More Products
Genentech/Xoma Raptiva Clears FDA, Priced At 25% Discount to Amevive
Genentech/Xoma Raptiva Clears FDA, Priced At 25% Discount to Amevive

Topics

Advertisement
UsernamePublicRestriction

Register

PS069393

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel